ClinicalTrials.gg
Active, not recruitingNCT06112743MEMENTOUpdated Sep 16, 2026

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 4 interventional study of Mavacamten in Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb. Active, not recruiting at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
63
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
12th of 21
63 · median 75
Started
2024
with 1 other
Phase 4
4 of 21
2 open now
Registered
15th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 12th largest by enrollment, is one of 2 that started in 2024, is one of 4 in phase 4, and was the 15th registered.

Cardiomyopathy, Hypertrophic

364 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the mavacamten impact on myocardial structure with cardiac magnetic resonance imaging (CMR) in adult participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) [New York Heart Association (NYHA) Functional Class II or III].

03

Conditions studied

  • Cardiomyopathy, Hypertrophic

Keywords

  • BMS-986427
  • MYK-461
  • Mavacamten
  • Obstructive Hypertrophic Cardiomyopathy (oHCM)
  • Camyzos
  • Cardiac Magnetic Resonance Imaging (CMR)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines as below:.
  • Left ventricular outflow tract (LVOT) peak gradient ≥ 30 mmHg and ≥ 50 mmHg after Valsalva or after exercise.
  • (LVEF) ≥ 55% at rest.
  • (NYHA) functional class II or III symptoms.

Exclusion criteria

Exclusion Criteria

  • A known infiltrative or storage disorder causing cardiac hypertrophy that mimics oHCM.
  • Documented obstructive coronary artery disease or history of myocardial infarction.
  • A history of resuscitated sudden cardiac arrest or life-threatening ventricular arrhythmia within 6 months prior to screening.
  • An implantable cardioverter defibrillator (ICD) or pacemaker, or another for cardiac magnetic resonance imaging (CMR).
  • Other protocol-defined inclusion/exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Mavacamten

    Drug: Mavacamten

Interventions

06

What researchers measure

Primary outcomes

  1. Composite of maximum left atrial volume index (LAVI) and left ventricular mass index (LVMI) at Week 48

    Participants achieving both of the following criteria at Week 48 cardiac magnetic resonance imaging (CMR) assessment: * A decrease of at least 5 mL/m2 in maximum LAVI from baseline * A decrease of at least 5 g/m2 in LVMI from baseline

    Time frame: At week 48

Secondary outcomes

  1. Proportion of participants who had at least 1 class of improvement from baseline in New York Heart Association (NYHA) class at Week 48

    Time frame: At week 48

  2. Change from baseline in maximum left atrial volume index (LAVI) at Week 48

    Time frame: At week 48

  3. Change from baseline in left ventricular mass index (LVMI) at Week 48

    Time frame: At week 48

  4. Incidence of major adverse cardiac events (MACE)

    Time frame: Up to 48 weeks

  5. Incidence of MACE-expanded events

    Time frame: Up to 48 weeks

  6. All-cause mortality

    Time frame: Up to 48 weeks

  7. Incidence of heart failure (HF) events

    Time frame: Up to 48 weeks

  8. Incidence of HF events with systolic dysfunction

    Time frame: Up to 48 weeks

  9. Incidence of atrial fibrillation (AF)/atrial flutter

    Time frame: Up to 48 weeks

  10. Incidence of cardiovascular (CV) mortality

    Time frame: Up to 48 weeks

  11. Incidence of ventricular tachyarrhythmias

    Time frame: Up to 48 weeks

  12. Incidence of nonvasovagal syncope and seizures

    Time frame: Up to 48 weeks

  13. Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Up to 48 weeks

  14. Severity of TEAEs

    Time frame: Up to 48 weeks

  15. Incidence of treatment emergent serious adverse events (SAEs)

    Time frame: Up to 48 weeks

  16. TEAEs leading to discontinuation from study intervention

    Time frame: Up to 48 weeks

  17. TEAEs leading to laboratory abnormalities

    Time frame: Up to 48 weeks

07

Study locations

23 sites
  • Local Institution - 0087
    West Hollywood, California 90048-1804, United States
  • Local Institution - 0003
    Atlanta, Georgia 30309, United States
  • Local Institution - 0093
    Boston, Massachusetts 02114, United States
  • Local Institution - 0090
    Cleveland, Ohio 44106, United States
  • Local Institution - 0086
    Pittsburgh, Pennsylvania 15212-4756, United States
  • Local Institution - 0017
    Houston, Texas 77030, United States
  • Local Institution - 0035
    Murray, Utah 84107-5701, United States
  • Local Institution - 0076
    Ciudad Autónoma de Buenos Aires, Buenos Aires 1093, Argentina
  • Local Institution - 0075
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1428ART, Argentina
  • Local Institution - 0079
    Pilar, Buenos Aires B1629ODT, Argentina
  • Local Institution - 0077
    Córdoba, Córdoba Province X5021FPQ, Argentina
  • Local Institution - 0074
    Rosario, Santa Fe Province S2000GAP, Argentina
  • Local Institution - 0080
    Buenos Aires, 1199, Argentina
  • Local Institution - 0015
    Camperdown, New South Wales 2050, Australia
  • Local Institution - 0085
    Chermside, Queensland 4032, Australia
  • Local Institution - 0005
    Melbourne, Victoria 3004, Australia
  • Local Institution - 0001
    Montreal, Quebec H1T 1C8, Canada
  • Local Institution - 0068
    Québec, Quebec G1V 4G5, Canada
  • Local Institution - 0058
    Lucerne, Luzern (de) 6000, Switzerland
  • Local Institution - 0029
    Lugano, Ticino (it) 6900, Switzerland
  • Local Institution - 0061
    Geneva, 1205, Switzerland
  • Local Institution - 0024
    Zürich (de), 8091, Switzerland
  • Local Institution - 0025
    Leeds, Yorkshire LS1 3EX, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jul 2026, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2023
First posted
Nov 1, 2023
StartActual
Jan 24, 2024
Primary completionActual
Jul 16, 2026
CompletionEst.
Jun 10, 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06112743
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Jan 24, 2024
Primary completion
Jul 16, 2026
Completion
Jun 10, 2027 (estimated)
Last update
Sep 16, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion